Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Nichol Miller"'
Autor:
Rebecca A. Gallego, Louise Bernier, Hui Chen, Sujin Cho-Schultz, Loanne Chung, Michael Collins, Matthew Del Bel, Jeff Elleraas, Cinthia Costa Jones, Ciaran N. Cronin, Martin Edwards, Xu Fang, Timothy Fisher, Mingying He, Jacqui Hoffman, Ruiduan Huo, Mehran Jalaie, Eric Johnson, Ted W. Johnson, Robert S. Kania, Manfred Kraus, Jennifer Lafontaine, Phuong Le, Tongnan Liu, Michael Maestre, Jean Matthews, Michele McTigue, Nichol Miller, Qiming Mu, Xulong Qin, Shijian Ren, Paul Richardson, Allison Rohner, Neal Sach, Li Shao, Graham Smith, Ruirui Su, Bin Sun, Sergei Timofeevski, Phuong Tran, Shuiwang Wang, Wei Wang, Ru Zhou, Jinjiang Zhu, Sajiv K. Nair
Publikováno v:
Journal of Medicinal Chemistry. 66:4888-4909
Autor:
Manfred Kraus, Joseph Tumang, Xianxian Zheng, Li-Chin Yao, Martin Wythes, Benoit J. Van den Eynde, Konstantinos Tsaparikos, Vince R. Torti, Nicole Streiner, Chad Ray, Virginie Rabolli, Romain Pirson, Nichol Miller, Reece Marillier, Karen Maegley, Wenlin Li, Marie-Claire Letellier, Jie Guo, Valeria R. Fantin, Christopher P. Dillon, Sofie Denies, Deepak Dalvie, Stefano Crosignani, Sandra Cauwenberghs, Danying Cai, Derek Bartlett, Gregory Driessens, Bruno Gomes
Table S2 shows a selectivity screen of PF-06840003 in in vitro pharmacological assays.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47698983ea67ec47db744f5010daf12a
https://doi.org/10.1158/1535-7163.22505134
https://doi.org/10.1158/1535-7163.22505134
Autor:
Manfred Kraus, Joseph Tumang, Xianxian Zheng, Li-Chin Yao, Martin Wythes, Benoit J. Van den Eynde, Konstantinos Tsaparikos, Vince R. Torti, Nicole Streiner, Chad Ray, Virginie Rabolli, Romain Pirson, Nichol Miller, Reece Marillier, Karen Maegley, Wenlin Li, Marie-Claire Letellier, Jie Guo, Valeria R. Fantin, Christopher P. Dillon, Sofie Denies, Deepak Dalvie, Stefano Crosignani, Sandra Cauwenberghs, Danying Cai, Derek Bartlett, Gregory Driessens, Bruno Gomes
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f74526ae85eebdbe19c754931a606d3
https://doi.org/10.1158/1535-7163.22505140
https://doi.org/10.1158/1535-7163.22505140
Autor:
Manfred Kraus, Joseph Tumang, Xianxian Zheng, Li-Chin Yao, Martin Wythes, Benoit J. Van den Eynde, Konstantinos Tsaparikos, Vince R. Torti, Nicole Streiner, Chad Ray, Virginie Rabolli, Romain Pirson, Nichol Miller, Reece Marillier, Karen Maegley, Wenlin Li, Marie-Claire Letellier, Jie Guo, Valeria R. Fantin, Christopher P. Dillon, Sofie Denies, Deepak Dalvie, Stefano Crosignani, Sandra Cauwenberghs, Danying Cai, Derek Bartlett, Gregory Driessens, Bruno Gomes
Table S1 shows the plasma protein binding and blood to plasma ratio in mouse, rat, dog and human. Table S3 shows the plasma concentrations following a single oral dose of PF-06840003. Figure S1 shows that PF-06840003 does not impact cell viability. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a821fe08534fa5982eef4c3eb5ce76
https://doi.org/10.1158/1535-7163.22505137
https://doi.org/10.1158/1535-7163.22505137
Autor:
Manfred Kraus, Joseph Tumang, Xianxian Zheng, Li-Chin Yao, Martin Wythes, Benoit J. Van den Eynde, Konstantinos Tsaparikos, Vince R. Torti, Nicole Streiner, Chad Ray, Virginie Rabolli, Romain Pirson, Nichol Miller, Reece Marillier, Karen Maegley, Wenlin Li, Marie-Claire Letellier, Jie Guo, Valeria R. Fantin, Christopher P. Dillon, Sofie Denies, Deepak Dalvie, Stefano Crosignani, Sandra Cauwenberghs, Danying Cai, Derek Bartlett, Gregory Driessens, Bruno Gomes
Tumors use indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies. IDO1 is i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b26f8def31d8e1dfcb01fcbd392ab72
https://doi.org/10.1158/1535-7163.c.6537964.v1
https://doi.org/10.1158/1535-7163.c.6537964.v1
Autor:
Mansi Arora, Justin Moser, Timothy E. Hoffman, Lotte P. Watts, Mingwei Min, Monica Musteanu, Yao Rong, Jordan Schneider, C Ryland Ill, Varuna Nangia, Manuel Sanclemente, John Lapek, Lisa Nguyen, Sherry Niessen, Stephen Dann, Todd van Arsdale, Mariano Barbacid, Nichol Miller, Sabrina L. Spencer
Publikováno v:
Cancer Research. 83:5992-5992
CDK2 is a core cell-cycle enzyme that phosphorylates a variety of substrates to drive progression through the cell cycle. CDK2 is hyperactivated in multiple cancers and is therefore an attractive therapeutic target. Here, application of a novel small
Autor:
Kephart Susan Elizabeth, Tran Khanh Tuan, Kevin Daniel Freeman-Cook, Sherry Niessen, James Solowiej, Buwen Huang, Qin Zhang, Douglas Carl Behenna, Inish O'Doherty, Sacha Ninkovic, Rose Ann Ferre, Andrea Hui, Nichol Miller, Jordan Carelli, Lisa Nguyen, Brion W. Murray, Robert Louis Hoffman, John Lapek, Rhys M. Jones, Meirong Xu, Stephen Dann, Sutton Scott Channing, Asako Nagata, Nanni Huser, Ravi Visswanathan, Zehnder Luke Raymond, Elaine E. Tseng, Britton Boras, You-Ai He, Michele McTigue, Wade Diehl, Cathy Zhang, Martha A. Ornelas
Publikováno v:
Journal of medicinal chemistry. 64(13)
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to add
Autor:
Meirong Xu, Koleen Eisele, Douglas Carl Behenna, John Chionis, Sutton Scott Channing, Cathy Zhang, Ping Wei, Ravi Visswanathan, Stephen Dann, B Jessen, Robert M. Hoffman, Britton Boras, Kevin Daniel Freeman-Cook, Michael A. White, Qin Zhang, Brion W. Murray, Jing Yuan, Sacha Ninkovic, Scott L. Weinrich, Nanni Huser, Jim Solowiej, Nichol Miller, Todd VanArsdale, Chaoting Liu
Publikováno v:
Cancer Research. 79:P6-20
This abstract was withdrawn by the authors. Citation Format: Dann S, Chionis J, Eisele K, Zhang Q, Liu C, Yuan J, Miller N, Murray B, Xu M, Solowiej J, Wei P, Weinrich S, Sutton S, Behenna D, Ninkovic S, Hoffman R, Freeman-Cook K, Jessen B, Huser N,
Autor:
Meredith McKean, Cesar A. Perez, Shumei Kato, Alexander I. Spira, Yan Xing, Hao Xie, Michael Millward, Anthony Olszanski, Ken Kobayashi, Nichol Miller, Paul Severson, Betty Tam, Caro Unger
Publikováno v:
Cancer Research. 82:CT248-CT248
Background: BRAFV600 alterations (BRAF Class (Cl) I alterations) encode a highly active monomeric oncogenic kinase that can be targeted by approved RAF kinase inhibitors (RAFi) in patients (pts) with melanoma (MEL), NSCLC, colorectal & anaplastic thy
Autor:
Paul L. Severson, Elifnur Yay Donderici, Nicole Zhang, Aleksandra Franovic, Nichol Miller, Eric Martin, Eric Murphy, Richard Williams
Publikováno v:
Cancer Research. 82:4122-4122
Background: Oncogenic BRAF alterations can be categorized by their distinct structural and signaling properties which lead to activation of the MAPK pathway: class I - kinase active signaling of BRAF mutant monomers; class II - kinase active signalin